Lenvatinib May Be Effective for Patients With, Without Prior VEGF Therapy Exposure

Share this content:
In thyroid cancer with and without prior exposure to VEGF therapy, the response rates and survival for lenvatinib have prompted further investigation.
In thyroid cancer with and without prior exposure to VEGF therapy, the response rates and survival for lenvatinib have prompted further investigation.

In patients with advanced, radioiodine-refractory, differentiated thyroid cancer (RR-DTC) with and without prior exposure to vascular endothelial growth factor (VEGF) therapy, the encouraging response rates, median time to response, and progression-free survival for lenvatinib have prompted further investigation in a phase 3 trial, a recent study published in the journal Cancer has shown.

For the phase 2 study, researchers enrolled 58 patients with RR-DTC who had disease progression during the previous 12 months.

All participants received lenvatinib 24mg once daily in 28-day cycles until disease progression, unacceptable toxicity, withdrawal, or death.

Results showed that after 14 or more months of follow-up, patients had an objective response rate of 50% (95% CI: 37-63). All responses were partial responses.

For patients who had received previous VEGF therapy, the objective response rate was 59% (95% CI: 33-82).

The study also showed a median time to response of 3.6 months, a median duration of response of 12.7 months, and a median progression-free survival of 12.6 months (95% CI: 9.99-16.1).

Researchers found that lower baseline levels of angiopoietin-2 were indicative of tumor response and longer progression-free survival.

RELATED: Acupuncture May Treat Radiation-Induced Anorexia in Thyroid Cancer

In regard to safety, the most common grade 3 or 4 treatment-related adverse events were weight loss, hypertension, proteinuria, and diarrhea.

Lenvatinib was approved by the U.S. Food and Drug Administration (FDA) earlier this year for the treatment of patients with locally recurrent or metastatic, progressive, RR-DTC.

Reference

  1. Cabanillas ME, Schlumberger M, Jarzab B, et al. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment. Cancer. 2015. [Epub ahead of print]. doi: 10.1002/cncr29395.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters